TRVI vs IDYA vs PTCT

For growth investors, IDEAYA Biosciences, Inc.

(IDYA) is the stronger pick with 30. 2% revenue growth year-over-year, versus 114. 5% for PTC Therapeutics, Inc. (PTCT). PTC Therapeutics, Inc. (PTCT) offers the better valuation at 8. 6x trailing P/E, making it the more compelling value choice. Analysts rate Trevi Therapeutics, Inc. (TRVI) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Trevi Therapeutics, Inc.

(TRVI) delivered a total return of +595. 6%, compared to +51. 3% for IDEAYA Biosciences, Inc. (IDYA). Over 10 years, the gap is even starker: PTCT returned +839. 5% versus TRVI's +80. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Trevi Therapeutics, Inc.

(TRVI) is the lower-risk stock at 1. 06β versus IDEAYA Biosciences, Inc. 's 1. 36β — meaning IDYA is approximately 28% more volatile than TRVI relative to the S&P 500. On balance sheet safety, Trevi Therapeutics, Inc. (TRVI) carries a lower debt/equity ratio of 0% versus 3% for IDEAYA Biosciences, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), IDEAYA Biosciences, Inc.

(IDYA) is pulling ahead at 30. 2% versus 114. 5% for PTC Therapeutics, Inc. (PTCT). On earnings-per-share growth, the picture is similar: PTC Therapeutics, Inc. grew EPS 264. 5% year-over-year, compared to 38. 3% for Trevi Therapeutics, Inc.. Over a 3-year CAGR, IDYA leads at 62. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

PTC Therapeutics, Inc.

(PTCT) is the more profitable company, earning 39. 4% net margin versus -52. 0% for IDEAYA Biosciences, Inc. — meaning it keeps 39. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PTCT leads at 49. 5% versus -72. 8% for IDYA. At the gross margin level — before operating expenses — IDYA leads at 97. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, PTC Therapeutics, Inc.

(PTCT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 13), +839. 5% 10Y return). Both have compounded well over 10 years (PTCT: +839. 5%, IDYA: +156. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TRVI is a small-cap quality compounder stock; IDYA is a small-cap high-growth stock; PTCT is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.